- Home
- PHAR vs SEAT Comparison
PHAR vs SEAT Comparison
Compare PHAR & SEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- SEAT
- Stock Information
- Founded
- PHAR 1988
- SEAT 2001
- Country
- PHAR Netherlands
- SEAT United States
- Employees
- PHAR N/A
- SEAT N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- SEAT Industrial Machinery/Components
- Sector
- PHAR Health Care
- SEAT Industrials
- Exchange
- PHAR Nasdaq
- SEAT Nasdaq
- Market Cap
- PHAR 731.1M
- SEAT 366.2M
- IPO Year
- PHAR N/A
- SEAT N/A
- Fundamental
- Price
- PHAR $10.31
- SEAT $1.78
- Analyst Decision
- PHAR Strong Buy
- SEAT Buy
- Analyst Count
- PHAR 3
- SEAT 11
- Target Price
- PHAR $30.00
- SEAT $4.49
- AVG Volume (30 Days)
- PHAR 3.6K
- SEAT 1.4M
- Earning Date
- PHAR 07-31-2025
- SEAT 08-05-2025
- Dividend Yield
- PHAR N/A
- SEAT N/A
- EPS Growth
- PHAR N/A
- SEAT N/A
- EPS
- PHAR N/A
- SEAT N/A
- Revenue
- PHAR $320,708,000.00
- SEAT $748,757,000.00
- Revenue This Year
- PHAR $13.31
- SEAT N/A
- Revenue Next Year
- PHAR $7.68
- SEAT $4.42
- P/E Ratio
- PHAR N/A
- SEAT N/A
- Revenue Growth
- PHAR 24.13
- SEAT 0.82
- 52 Week Low
- PHAR $6.65
- SEAT $1.44
- 52 Week High
- PHAR $12.61
- SEAT $5.74
- Technical
- Relative Strength Index (RSI)
- PHAR 43.60
- SEAT 48.12
- Support Level
- PHAR $9.99
- SEAT $1.82
- Resistance Level
- PHAR $10.49
- SEAT $2.06
- Average True Range (ATR)
- PHAR 0.34
- SEAT 0.14
- MACD
- PHAR -0.14
- SEAT 0.02
- Stochastic Oscillator
- PHAR 7.45
- SEAT 45.65
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About SEAT Vivid Seats Inc.
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.